Insider Buying Signals, June 1–8, 2026
~$127M in qualifying open-market purchases across 20 US-listed entities for the June 1–8 window. Headline signals: HOOD Director Malka Meyer's $35.1M two-tranche cluster, Insperity CEO Sarvadi's $15.5M seller-to-buyer pivot, Summit Therapeutics' Co-CEO+CFO $2.92M post-ASCO dip, and ContextLogic's two-insider debut. Serial accumulators Aurinia ($62M+) and TXO ($65M+) extend campaigns.
The June 1–8 window produced roughly $127M in qualifying open-market purchases across 20 US-listed entities, after removing one transaction reclassified as merger arbitrage (see FONR note below). 1 The week's most striking structural feature is cluster density: four separate companies saw multiple insiders file Form 4 purchases in the same seven-day window — Norwegian Cruise Line (7 insiders), Summit Therapeutics (3 insiders), Insperity (4-insider week, including the CEO's two tranches), and ContextLogic (2-insider debut cluster). That is the highest single-week cluster count in this channel's tracked history.
Two serial accumulators — Aurinia Pharmaceuticals CEO Kevin Tang and TXO Partners founder Bob R. Simpson — extended buying campaigns that now exceed $62M and $65M respectively, with no catalyst explaining either purchase batch. The week's data-quality note: SVRE/Visionwave Holdings reported a multi-billion-dollar "Director buy" on Finviz that is a confirmed 32-bit integer overflow in the SEC filing XML; the transaction is excluded. 1
This week at a glance
| Insider | Title | Ticker | Amount | Date(s) | Tier |
|---|---|---|---|---|---|
| Malka Meyer | Director | HOOD | $35.1M (cluster) | May 28 + Jun 3 | Conviction |
| Kevin Tang | CEO | AUPH | $12.46M | May 29 | Conviction / Serial |
| Guofu Ye + Yunyun Yang | Chair + exec | MNSO | ~$13.8M (cluster) | Jun 1–4 | Conviction |
| Bob R. Simpson | Dir / 10% owner | TXO | $8.23M | Jun 2 | Serial |
| Paul Sarvadi | CEO | NSP | $7.93M (+$4.69M prior) | Jun 3 (+May 18) | Conviction |
| Mike Weinbach | CEO-Elect | RDN | $5.77M | Jun 1 | Conviction |
| Zanganeh + Duggan + CFO | Co-CEOs + CFO | SMMT | $2.92M (cluster) | Jun 4 | Conviction |
| Bernardo Hees | Director | DNUT | $2.12M | Jun 1–4 | Speculative |
| Bobbili Raja + Paul S. Levy | Dir / 10% + Dir | LOGC | $2.26M (cluster) | May 26–Jun 3 | Speculative |
| Ernest Rady | Exec COB / 10% | AAT | $234K | Jun 1 | Serial |
| Haveli Investments | Dir / 10% | BLND | $421K | Jun 3 | Speculative |
| Hilary Shane | 10% owner | FONR | $4.11M | Jun 2 | Reclassified† |
† FONR: merger arbitrage, not a conviction signal — see note below. All other transactions are Form 4 code-P open-market purchases. Data: OpenInsider. 1
コンテンツカードを読み込んでいます…
Conviction-tier signals
HOOD — Robinhood: Director's $35.1M while CEO and CFO sell
Malka Meyer, Director of Robinhood Markets (NASDAQ: HOOD), purchased shares on two separate dates: $20M on May 28, then another $15.1M on June 3, combining for $35.1M — the week's largest single-insider dollar figure. 1
The divergence with executive-level insiders is the key structural note here. CEO Vlad Tenev and the CFO were selling during the same period. Director-vs.-executive divergence is a yellow flag in isolation, but it may also reflect different 10b5-1 plan structures: pre-set automatic selling plans by operating executives are common at tech companies, whereas a board director's discretionary buy carries a different classification. The full Form 4 filings would need to confirm transaction codes to separate plan-driven sales from discretionary ones. Without that confirmation, the CEO/CFO selling warrants treating this signal at a slight discount.
The business backdrop for the June 3 purchase: Robinhood removed its Pattern Day Trader (PDT) restriction — the rule that had required a minimum $25,000 account balance to execute more than three day trades per week — effective June 4, following FINRA's adoption of new margin rules. 2 Separately, the Digital Asset Clarity Act cleared the Senate Banking Committee in mid-May, drawing a clearer line between SEC and CFTC jurisdiction over crypto — a modest regulatory tailwind for Robinhood's crypto products. 3 Robinhood's Q1 2026 EPS of $0.38 missed consensus of $0.40, with crypto trading revenue down sharply, though total revenue of $1.1B rose 15.1% year-over-year. 1 Stock is down roughly 27% year-to-date.
Meyer's two tranches — $20M then $15.1M within six days — follow a pattern of escalating conviction that this screen treats as a stronger signal than a single large purchase.
AUPH — Aurinia Pharmaceuticals: CEO's $62M series with no new catalyst
Kevin Tang, CEO of Aurinia Pharmaceuticals (NASDAQ: AUPH), purchased approximately 815,000 shares at ~$15.28 on May 29, totaling $12.46M. 1 This is the latest tranche in a buying campaign that has now crossed $62.3M at the CEO level.
The absence of a catalyst is what distinguishes this signal. Aurinia reported Q1 2026 revenue of $77.71M and net income of $34.36M, and reaffirmed its full-year 2026 revenue guidance of $315M–$325M — all disclosed on May 7, three weeks before the purchase. 4 There was no new catalyst between the May 7 earnings call and Tang's May 29 purchase — no pipeline update, no guidance revision, no analyst upgrade. Tang is buying against a backdrop of full public information, in size, repeatedly. That profile is the core of why this signal is treated as high-conviction despite Aurinia's single-product dependency on Lupkynis and an early-stage pipeline.
MNSO — Miniso Group: Chairman buys on two exchanges simultaneously
Guofu Ye (Chairman and 10% owner) and Yunyun Yang together purchased approximately $13.8M worth of Miniso Group (NYSE: MNSO) ADRs in the June 1–4 window, while Ye separately acquired 2.1 million shares on the Hong Kong Exchange (ticker 09896), pushing his stake to 63.9%. 5
ADR ratio note: One MNSO ADR equals four ordinary shares. The HKEX price of approximately HK$25.94 maps to roughly $13.30 per ADR (4 × HK$25.94 ÷ 7.8), confirming parity with the NYSE MNSO price near $13.31. Any $3.29 figure appearing in older data sources is likely a pre-ratio-adjustment artifact or data error.
The stock has declined roughly 50% from its 52-week high of $26.74. Ye is buying into that decline at a forward P/E of approximately 8.47, against a Q1 2026 revenue growth backdrop that the company describes as strong. The company has also been running a Rule 10b5-1 share repurchase program, having repurchased 7.92 million shares — so the buyback and the chairman's personal buying are running in parallel.
One offset worth noting: Legal & General cut its MNSO position by 22% in the same period, representing institutional selling against the chairman's buying.
NSP — Insperity: CEO crosses from seller to buyer with $15.5M
Paul Sarvadi, CEO of Insperity (NYSE: NSP, a professional employer organization providing HR outsourcing services to small and mid-sized businesses), made two purchases across the coverage window: 201,987 shares at $23.21 ($4.69M) on May 18, then 233,000 shares at $34.05 ($7.93M) on June 3, combining for roughly $15.5M. 6
The directional change matters here. Sarvadi was a net seller before this sequence — the shift to aggressive buying at two different price points over a 16-day span is a structural break from his prior pattern. The stock has fallen roughly 44–47% from its 52-week high to the current $33–35 range. Insperity's Q1 2026 revenue rose just 1.7% year-over-year, and FY2026 EPS guidance of $1.60–$2.60 is at the low end of the company's historical range — a setup that suggests Sarvadi is buying what he believes is a cyclical earnings trough, not a structurally impaired business. 7
The quarterly cash dividend of $0.60 was declared on June 4, payable June 18 — Sarvadi's June 3 purchase preceded that announcement by one day.
The research summary notes a potential 4-insider cluster at NSP this week; the summary's phrasing ("4-insider") includes Sarvadi's two separate tranches as distinct events alongside potentially other board members. Only Sarvadi's transactions have been individually confirmed in the research data, so the cluster count of 4 should be treated as approximate pending full Form 4 verification.
RDN — Radian Group: new CEO-Elect's $5.77M opening buy on day one
Mike Weinbach, appointed CEO-Elect of Radian Group (NYSE: RDN) with an effective date of June 1, purchased shares totaling $5.77M on his first day in the role. 8 Weinbach formally takes over from Rick Thornberry on August 13, 2026; Thornberry announced his retirement intent on May 21 after leading the company for nearly a decade.
The transaction carries a specific caveat: Weinbach is eligible for NYSE Rule 303A.08 employment-inducement equity grants. Such grants — stock awards that compensate a new executive for compensation forfeited at a prior employer — do not require shareholder approval and are distinct from open-market discretionary purchases. The $5.77M figure needs to be confirmed against the Form 4 transaction code to determine whether this was a pure open-market buy (code P) or partly associated with an employment award.
Taking the purchase at face value as a discretionary buy: Radian completed its $1.7 billion acquisition of Inigo Limited (a Lloyd's of London specialty insurer) in February 2026, entering global specialty insurance markets. Radian held its 2026 Investor Day in New York on June 4, articulating its long-term strategy as a diversified specialty insurance platform. 8 A new CEO choosing to hold $5.77M of personal equity ahead of an Investor Day is a positive signal, but less clean than a mid-tenure discretionary buy.
One conflicting data point: Director Margaret Leyden sold $71,601 worth of RDN shares on May 29.
SMMT — Summit Therapeutics: Co-CEOs and CFO buy the ASCO selloff
Summit Therapeutics (NASDAQ: SMMT) Co-CEOs Maky Zanganeh and Robert Duggan, joined by the CFO, collectively purchased $2.92M of SMMT shares on June 4 — a 3-insider cluster following a sharp post-ASCO selloff. 9
The clinical data context: Summit presented two datasets at ASCO 2026 for ivonescimab, its anti-PD-1/VEGF bispecific antibody co-developed with Akeso.
- HARMONi-6 (Phase III, squamous non-small cell lung cancer): ivonescimab + chemotherapy vs. tislelizumab + chemotherapy produced an OS hazard ratio of 0.66 — a 34% reduction in mortality risk — with median overall survival of 27.89 months vs. 23.69 months and a 24-month OS rate of 64.7% vs. 48.6%. 10
- AK112-206 (Phase II, first-line MSS colorectal cancer): objective response rate 70.8%, disease control rate 100.0%, 9-month progression-free survival rate 76.1%. 10
Despite those results, SMMT fell 11% on June 1. Jefferies analyst Faisal Khurshid noted that the median OS improvement of 4.2 months appeared smaller than the hazard ratio suggested, and raised questions about whether the data from Chinese patients would translate to US/European populations. 9 Evercore's Cory Kasimov, however, described the OS data as clearing "even the highest investor expectations."
The FDA has accepted ivonescimab's BLA, with a PDUFA target action date of November 14, 2026. The Co-CEOs and CFO purchasing $2.92M into the selloff — three days after the market's negative reaction — represents management backing its own read of the clinical data against sell-side skepticism. SMMT is down roughly 53% from its 52-week high. The November 14 PDUFA date provides a concrete near-term catalyst for resolution.
コンテンツカードを読み込んでいます…
Serial accumulation
TXO — TXO Partners: $65M+ campaign extends into June
Bob R. Simpson, founder, Director, and 10% owner of TXO Partners LP (NYSE: TXO, a Williston Basin oil and gas master limited partnership), purchased approximately $8.23M on June 2, continuing a buying campaign that has now crossed $65M at his personal level. 11 His post-purchase position: approximately 8.7 million units.
TXO's Q1 2026 distribution was $0.36 per unit. The company plans $70M in capital expenditure for 2026 alongside asset divestitures to reduce leverage — a posture that reflects cautious balance sheet management against what Simpson appears to view as an undervalued energy asset. TipRanks notes analysts maintained a positive stance while cutting price targets, with caution around distribution sustainability at lower commodity prices. 11 Oil prices have recovered from approximately $52 to around $80 over recent months, providing the underlying commodity support. 11
Simpson's June 2 purchase follows the $3.91M tranche on May 15 and an $8.23M tranche filed on June 2. His prior entries from 2024 and 2025 at higher prices are currently underwater, meaning he is buying into a losing position — the same pattern as last week, now at a larger cumulative scale.
コンテンツカードを読み込んでいます…
AAT — American Assets Trust: Rady's 7th session in 12 trading days
Ernest Rady, Executive Chairman and 10% owner of American Assets Trust (NYSE: AAT, a West Coast REIT), purchased 10,000 shares at $23.40 on June 1, totaling $234,000. Post-purchase position: 13,509,443 shares. 12 This was his 7th buying session across the preceding 12 tracked trading days, bringing his estimated 2026 accumulation to roughly $16.4M+ at a blended range of $18.81–$23.40. There have been zero insider sales in the tracked period.
At $23.40, Rady is buying at the upper end of his 2026 purchase range — the same pattern noted last week, of accumulating into price strength rather than dips. His total share count (13.5M shares at $23.40 ≈ $316M in personal equity exposure in this single stock) is the relevant scale anchor for sizing the conviction read.
Speculative-tier entries
LOGC — ContextLogic Holdings: second director joins Bobbili Raja
A second director at ContextLogic Holdings (OTCQB: LOGC, a former e-commerce marketplace now in a strategic pivot) initiated buying this week. Paul S. Levy (Director) purchased 25,693 shares at $9.04 on June 1 ($232,344) and 99,428 shares at $9.05 on June 3 ($899,618), combining for $1,131,962 over two trading days — creating a 2-insider cluster alongside existing accumulator Bobbili Raja. 13
Levy's prior LOGC transaction history on OpenInsider: zero. This is a debut position. Raja last purchased on May 26 ($1.13M) and has been buying since February 2026, with a blended average in the $7.00–$9.05 range. The research summary identifies Levy's background as a gap — whether he is a new board appointee, an activist, or an existing holder building a disclosed stake is not confirmed by available sources, which reduces the signal weight. 13 LOGC trades on OTCQB (not a major exchange), which carries liquidity constraints.
DNUT — Krispy Kreme: Director Hees buys 630K shares at $3.36
Bernardo Hees, Director of Krispy Kreme (NASDAQ: DNUT), purchased 630,111 shares through BHBK LLC at a weighted average of approximately $3.36 across four consecutive trading days (June 1–4), totaling $2,116,727. 14 Current stock price: approximately $3.51.
DNUT has experienced a pronounced multi-year decline. Hees' purchase at $3.36 places him near the stock's apparent floor, and the four-day spread (rather than a single block) suggests intentional execution over time. The speculative-tier classification reflects the limited publicly available context for this purchase — no earnings catalyst or announced strategic action coincides with the buy window.
BLND — Blend Labs: Haveli resumes underwater accumulation
Haveli Investments L.P. (Director and 10% owner of Blend Labs, NASDAQ: BLND, a mortgage and banking software company), purchased 268,606 shares at $1.57 on June 3, totaling $421,335. Post-purchase position: 16,547,794 shares. 15
Haveli's prior BLND purchases: $3.03–$3.11 per share (November 2025) and $1.37–$1.49 (May 2026). The current $1.57 purchase is above its May tranche and roughly half its November 2025 entry — meaning the November cost is approximately 50% underwater. This is a 16+ month accumulation with consistent buying on each leg down. The conflicting signal: multiple Blend Labs employees at the operational level (Head of Blend, Head of Revenue, General Counsel, Principal Accounting Officer) filed Form 4 sales during the same period. Institutional commitment vs. employee liquidation is a split that historically warrants reading with caution.
FONR — merger arbitrage note (excluded from signal pool)
Hilary Shane filed a $4.11M purchase in Fonar Corp (FONR) on June 2, part of an approximately $10.6M buying campaign over two weeks. This is excluded from the conviction signal pool. 16
The timeline makes the classification clear: Fonar shareholders voted to approve the going-private merger on May 28. Shane's purchases occurred after that vote and before the company's Nasdaq delisting on June 3. 17 Buying after a merger has been approved but before delisting is arbitrage — purchasing at a discount to the merger consideration with a near-certain exit. It is not a signal about Fonar's business fundamentals or management's confidence in the stock.
Prior week trackers: who paused
Eight active buyers from last week's screen showed no new qualifying purchases in the June 1–8 window. 1
| Ticker | Last buy | Last buyer | Notes |
|---|---|---|---|
| SLMT | May 21 | CEO Sade + Dir Maimon | $11.42M cluster; paused 2 weeks |
| HLNE | May 26–27 | Exec Co-Chairman Rogers | $9.99M; paused 1 week |
| COE | May 22 | CEO Huang | $76M+ in 2026; paused 2 weeks |
| WGS | May 18 | Casdin Capital | $21.46M; paused 4 weeks |
| FBIN | May 19–20 | Dir Garden / Trian | $15.66M; paused 4 weeks |
| RSG | May 14 | Cascade Investment / Gates | $101.84M; paused 4 weeks |
| CSAN | Apr 10 | CEO Martins | $23.82M; paused ~8 weeks |
| GOLD | May 22 | Tether Global | $2.52M; paused 1 week |
Cascade/Gates at RSG has now been quiet for four consecutive weeks after a $101M+ position build. WGS/GeneDx (Casdin Capital, $21.46M) and FBIN (Trian, $15.66M) are also in their fourth week of no new activity. These pauses do not invalidate the prior signal, but they reduce the near-term momentum read.
Data-integrity note
SVRE (Visionwave Holdings / VWAV): Finviz reported two Director buys totaling $2.37B on June 4–5 at $4.00 per share. OpenInsider shows a single May 21 trade where both the "owned shares after" field and the "value" field read exactly 2,147,483,647 — which is 2³¹−1, the maximum value of a signed 32-bit integer. 1 This is a data overflow artifact in the SEC filing's XML, not an actual transaction. SVRE is excluded from all signal counts.
Cover: AI-generated illustration.
参考ソース
- 1OpenInsider: Top Insider Purchases of the Week
- 2Robinhood is Now Open to Agents
- 3Digital Asset Clarity Act Puts Robinhood's Crypto Regulation Risks In Focus
- 4Stronger Q1 Profitability And Reaffirmed 2026 Outlook Could Be A Game Changer For Aurinia (AUPH)
- 5MNSO Chairman Buys 2.1M Shares; Stake Rises to 63.9%
- 6Insperity (NYSE:NSP) Stock Price Up 6.4% — What's Next?
- 7Insperity sets $0.60 quarterly cash dividend
- 8Radian CEO Rick Thornberry Announces Intent to Retire; Board Appoints Mike Weinbach as His Successor
- 9Summit drops as concerns over older patients cloud cancer trial data
- 10Summit highlights strong ivonescimab ASCO 2026 data — SMMT 8-K Filing
- 11Major Insider Move Signals Bold Confidence in TXO Energy Partners LP
- 12AAT — American Assets Trust, Inc. — SEC Form 4 Insider Trading Screener
- 13LOGC — Contextlogic Holdings Inc. — SEC Form 4 Insider Trading Screener
- 14Krispy Kreme director buys 630K DNUT shares
- 15BLND — Blend Labs, Inc. — SEC Form 4 Insider Trading Screener
- 16FONAR Announces Financial Results for Fiscal 2026 Third Quarter and Nine-Month Period
- 17Fonar Completes Merger and Transitions to Private Company
このコンテンツについて、さらに観点や背景を補足しましょう。